Veru Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mitchell S. Steiner
- Full Time Employees
- 20
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2916 North Miami Avenue Miami FL United States of America 33127
- IPO Date
- Feb 11, 1999
- CIK
- 0000863894
- Website
- verupharma.com
- Similar Companies
- Business
- Veru Inc. is a late clinical-stage biopharmaceutical company headquartered in Miami, Florida, with offices in London and Kuala Lumpur, focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, oncology, and acute respiratory distress syndrome (ARDS). The company’s core products and services include two late-stage novel small molecule drug candidates: enobosarm, a selective androgen receptor modulator (SARM) developed for obesity management and advanced breast cancer; and sabizabulin, a microtubule disruptor aimed at treating inflammation in atherosclerotic coronary artery disease and viral-induced ARDS. Veru also formerly commercialized the FC2 Female Condom but sold this business in late 2024 to focus exclusively on its biopharmaceutical pipeline. Recent major company changes include the sale of the FC2 Female Condom business for $18 million in December 2024, marking a strategic shift to concentrate resources on late-stage clinical drug development. In 2025, Veru announced the selection of a novel modified release oral formulation of enobosarm developed in collaboration with Laxxon Medical, leveraging proprietary SPID® technology to advance the drug’s clinical profile for chronic weight loss management. The company is conducting a fully enrolled Phase 2b clinical trial evaluating enobosarm to preserve muscle and enhance fat loss in patients undergoing glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy for weight loss. Sabizabulin continues development for atherosclerotic cardiovascular disease and viral-induced ARDS. Veru maintains ongoing clinical programs targeting an improved quality of weight loss and inflammation-related conditions. Founded in 1996, Veru operates primarily in the U.S. with a global reach through offices in the UK and Malaysia. The company serves diverse patient populations in metabolic, oncologic, and inflammatory disease markets. Its strategic focus and repositioning following the FC2 business divestiture underscore a commitment to innovation in small molecule therapeutics aimed at cardiometabolic, oncologic, and inflammatory disorders. Veru’s product pipeline and development efforts reflect a robust late-stage portfolio in specialized pharmaceutical markets.
Company News
Veru to Participate in Fireside Chat at the 2026 Cantor Global Healthcare Conference
Veru Inc. (VERU) Q3 2026 Earnings Call Transcript
Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss
Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th
Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference
Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
Veru (NASDAQ:VERU) Share Price Crosses Below 200 Day Moving Average – Here’s Why
Veru (NASDAQ:VERU) Stock Passes Below 200 Day Moving Average – Should You Sell?
Veru (NASDAQ:VERU) Shares Cross Below 200 Day Moving Average – Here’s Why
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript
Flora Growth (NASDAQ:FLGC) and Veru (NASDAQ:VERU) Financial Review
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
Veru Inc. (VERU) Q4 2025 Earnings Call Transcript
Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress